Wealth Enhancement Advisory Services LLC Purchases 105,368 Shares of Pfizer Inc. $PFE

Wealth Enhancement Advisory Services LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,414,548 shares of the biopharmaceutical company’s stock after acquiring an additional 105,368 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Pfizer were worth $86,841,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer during the 3rd quarter worth $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer in the second quarter valued at about $30,000. True Wealth Design LLC raised its stake in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Pfizer in the second quarter worth about $32,000. Finally, Sagard Holdings Management Inc. purchased a new stake in shares of Pfizer during the second quarter worth about $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.98 on Monday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The business’s 50 day moving average price is $26.68 and its 200 day moving average price is $25.61. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm has a market cap of $153.41 billion, a P/E ratio of 19.84 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period last year, the firm posted $0.63 EPS. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. HSBC increased their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Bank of America cut their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.14.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.